Today: 11 June 2026
London Stock Exchange at Record Highs – Inside the Historic Market’s Brexit Battle and 2025 Revival

UK stocks today (6 Nov 2025): FTSE 100 edges lower before BoE decision; Sainsbury lifts profit guidance, ITV warns on Q4 ads, AstraZeneca beats

LONDON — Thursday, 6 November 2025

At a glance

  • FTSE 100 trades slightly lower as investors await the Bank of England’s rate call; sterling holds near multi‑month lows.
  • Construction PMI slumps to 44.1 in October, the sharpest contraction in over five years, underscoring a soft UK backdrop.
  • Earnings & updates:
    • J Sainsbury raises FY retail underlying operating profit guidance to “more than £1bn” and confirms an 11p special dividend. corporate.sainsburys.co.uk
    • ITV flags ~9% YoY decline in Q4 total ad revenue and unveils £35m temporary savings.
    • AstraZeneca beats Q3 revenue and core EPS but keeps full‑year guidance unchanged.
    • Smith & Nephew shares drop ~9% on softer US knee‑implant sales.
    • Diageo posts flat organic net sales in fiscal Q1 (volume +2.9%) and trims full‑year sales outlook.
    • Hikma reaffirms 2025 guidance but lowers medium‑term growth targets.
    • LSEG announces a private‑markets data partnership with Nasdaq.

Market snapshot: waiting on Threadneedle Street

UK equities were fractionally lower by late morning, with traders staying cautious ahead of the Bank of England’s midday decision and press conference. The FTSE 100 drifted as much as about 0.3%, while sterling hovered near recent lows against major peers amid growth concerns and budget uncertainty later this month.

Fresh data reinforced the slowdown narrative: the S&P Global/CIPS Construction PMI fell to 44.1 in October (from 46.2), marking the fastest drop in activity since May 2020 and the longest downturn since the financial crisis. Civil engineering led the decline, with housing also weak.

One pocket of strength: UK bank shares modestly outperformed after reports the sector may avoid a punitive tax raid in the upcoming Budget, lifting the FTSE 350 Banks index.


Big movers & newsmakers

Sainsbury: guidance upgrade, special payout

J Sainsbury (SBRY) said first‑half trading was ahead of expectations and raised its full‑year retail underlying operating profit target to “more than £1bn.” It also confirmed an 11p special dividend on 19 December and outlined additional buyback plans linked to its bank disposals. The retailer cited grocery volume growth, improving value perception and cost savings. corporate.sainsburys.co.uk

ITV: strong Studios & digital, but Q4 ad headwinds

ITV (ITV) reported +2% group revenue YTD to £2.80bn, driven by +11% Studios and +15% digital ad growth. However, management warned Q4 total advertising revenue is expected to be down ~9% YoY, citing broad caution ahead of the late‑November Budget. ITV will make £35m temporary savings (including £20m by moving content into 2026) to offset the revenue hit.

AstraZeneca: beats, but no guidance raise

AstraZeneca (AZN) delivered a Q3 beat on revenue and core EPS thanks to oncology and cardiovascular drugs, but left its full‑year outlook unchanged, which some investors had hoped would be lifted. The company highlighted pipeline progress and reiterated long‑term ambitions.

Smith & Nephew: revenue miss bites

Smith & Nephew (SN.) shares fell around 9% after Q3 revenue (~$1.50bn) missed estimates, with US knee‑implant sales singled out as a weak spot. The company kept its annual revenue and margin guidance unchanged, but the US orthopaedics softness dominated sentiment.

Diageo: flat volumes up, price/mix down; outlook nudged

Diageo (DGE) posted flat organic net sales in fiscal Q1 (volume +2.9%) as growth in Europe, LAC and Africa was offset by Chinese white spirits weakness and a softer US spirits market. Diageo now expects FY26 organic net sales to be flat to slightly down, but still targets ~$3bn free cash flow this year as its “Accelerate” cost‑saving programme progresses. www.diageo.com

Hikma: 2025 intact, medium‑term trimmed

Hikma (HIK) reaffirmed 2025 guidance (group revenue growth 4–6%; core operating profit $730–$750m), but revised lower its 2024–2027 CAGR and Injectables margin expectations as its Bedford US facility timeline pushes out toward late 2027.

LSEG x Nasdaq: private‑markets data tie‑up

London Stock Exchange Group (LSEG) unveiled a strategic partnership with Nasdaq to distribute private‑markets datasets (including eVestment content) via LSEG Workspace and datafeeds—an extension of LSEG’s recent push into private‑company infrastructure.


Why it matters

  • The BoE decision arrives into a weak domestic backdrop (construction slump, cautious consumers and advertisers), alongside a soft currency—all levers that can magnify policy impact on bank, housebuilder and domestically focused mid‑cap shares.
  • Corporate updates show a bifurcated market: staples/retailers are leaning on cash returns and execution (Sainsbury), media is feeling the cyclical ad slowdown (ITV), while healthcare names are moving on pipeline and mix (AstraZeneca; Smith & Nephew).
  • Banks’ relative outperformance today underlines how fiscal signals can swing sector leadership in the run‑up to November’s Budget.

What to watch next (today)

  • Bank of England policy decision & vote split — market reaction in gilts, sterling, banks, and UK domestic cyclicals.
  • Company calls and press briefings from today’s reporters (notably AstraZeneca, ITV, Diageo, Hikma) for colour on 2026 planning, cost actions, and demand signals.

Sources & further reading

  • Market & macro: UK stocks and FX pre‑BoE; UK banks rally; UK Construction PMI.
  • Company updates: Sainsbury H1 results; ITV Q3 trading update; AstraZeneca Q3; Smith & Nephew Q3 price reaction; Diageo F26 Q1; Hikma trading update; LSEG–Nasdaq partnership.

This report is for information only and does not constitute investment advice. Market levels and share prices referenced above reflect conditions reported during the UK morning session on 6 November 2025.

Stock Market Today

  • Live Cattle Futures Edge Higher Amid Mixed USDA Beef Prices
    June 11, 2026, 10:54 AM EDT. Live cattle futures rose by $1.45 to $1.60 across most front months on Wednesday, with December delivery slightly down. Feeder cattle futures gained $2.40 to $2.90 by midday. Open interest increased by 1,293 contracts. Managed money trimmed net long positions in live cattle futures and options by 7,083 contracts, totaling 101,265, while feeder cattle spec funds reduced holdings by 470 contracts. USDA reported a decline in wholesale boxed beef prices, with Choice boxes down $1.68 to $359.36 and Select down $3.15 to $344.88. Federally inspected cattle slaughter rose to an estimated 123,000 head Wednesday, exceeding last week but falling short of last year. The mixed data signals ongoing volatility in cattle markets as traders assess supply and demand factors.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Interstellar Comet 3I/ATLAS: A Visitor from Beyond the Solar System
Previous Story

Comet 3I/ATLAS today (6 Nov 2025): China’s Mars orbiter snaps new photos as the interstellar visitor turns bluer and shows puzzling acceleration

Bubble or Boom? Magnificent Seven Stocks Face Critical Earnings Showdown
Next Story

Alphabet (GOOGL) Stock Today, Nov 7, 2025: Shares Slip ~2.6% as YouTube TV–Disney Blackout Persists; DOJ Clears $32B Wiz Deal

Go toTop